Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome.

The atypical form of the kidney disease hemolytic uremic syndrome (aHUS) is associated with defective complement regulation. In addition to mutations in complement regulators, factor H (FH)-specific autoantibodies have been reported for aHUS patients. The aim of the present study was to understand the role of these autoantibodies in aHUS. First, the binding sites of FH autoantibodies from 5 unrelated aHUS patients were mapped using recombinant FH fragments and competitor antibodies. For all 5 autoantibodies, the binding site was localized to the FH C-terminus. In a functional assay, isolated patient IgG inhibited FH binding to C3b. In addition, autoantibody-positive patients' plasma caused enhanced hemolysis of sheep erythrocytes, which was reversed by adding FH in excess. These results suggest that aHUS-associated FH autoantibodies mimic the effect of C-terminal FH mutations, as they inhibit the regulatory function of FH at cell surfaces by blocking its C-terminal recognition region.

[1]  John D Lambris,et al.  The C-terminus of complement factor H is essential for host cell protection. , 2007, Molecular immunology.

[2]  G. Remuzzi,et al.  The interactive Factor H–atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models , 2007, Human mutation.

[3]  G. Remuzzi,et al.  Hemolytic uremic syndrome: a factor H mutation (E1172Stop) causes defective complement control at the surface of endothelial cells. , 2007, Journal of the American Society of Nephrology : JASN.

[4]  M. Pangburn,et al.  Critical Role of the C-Terminal Domains of Factor H in Regulating Complement Activation at Cell Surfaces1 , 2006, The Journal of Immunology.

[5]  M. Oppermann,et al.  The C‐terminus of complement regulator Factor H mediates target recognition: evidence for a compact conformation of the native protein , 2006, Clinical and experimental immunology.

[6]  Stefan Heinen,et al.  Factor H and atypical hemolytic uremic syndrome: mutations in the C-terminus cause structural changes and defective recognition functions. , 2005, Journal of the American Society of Nephrology : JASN.

[7]  W. Fridman,et al.  Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. , 2005, Journal of the American Society of Nephrology : JASN.

[8]  S. Rodríguez de Córdoba,et al.  Functional analysis in serum from atypical Hemolytic Uremic Syndrome patients reveals impaired protection of host cells associated with mutations in factor H. , 2004, Molecular immunology.

[9]  Stefan Heinen,et al.  Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. , 2003, The Journal of clinical investigation.

[10]  S. Meri,et al.  Complement C3b/C3d and Cell Surface Polyanions Are Recognized by Overlapping Binding Sites on the Most Carboxyl-Terminal Domain of Complement Factor H1 , 2002, The Journal of Immunology.

[11]  D. Pérez-Caballero,et al.  Structural and functional characterization of factor H mutations associated with atypical hemolytic uremic syndrome. , 2002, American journal of human genetics.

[12]  M. Pangburn,et al.  Cutting Edge: Localization of the Host Recognition Functions of Complement Factor H at the Carboxyl-Terminal: Implications for Hemolytic Uremic Syndrome1 , 2002, The Journal of Immunology.

[13]  S. Cutillo.  [Hemolytic-uremic syndrome]. , 1973, La Pediatria.